Erasca's Cash Runway Could End Before Its Pan-RAS Bet Pays Off

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Erasca typically reports earnings after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers and management commentary.

Erasca's post-earnings price behavior has been relatively muted compared to typical biotech volatility, with an average absolute Day 0 move of 4.45% and Day +1 move of 3.71%. However, the intraday volatility tells a different story—the average Day 0 range of 7.76% and Day +1 range of 11.17% indicate significant intraday swings even when the closing move is modest.

The most dramatic reaction came in March 2026, when the stock fell 5.48% on earnings day and extended losses to 7.03% the following session, with a Day +1 range exceeding 13%. This coincided with the company's strategic decision to terminate the naporafenib program and focus resources on the RAS franchise. Conversely, the November 2025 report saw a sharp 12.29% Day 0 gain, though much of that reversed the following day.

More recently, the August 2026 report (most recent quarter) showed a modest 1.05% Day 0 gain and 1.47% Day +1 gain, suggesting investors took the Q2 miss in stride given the positive ERAS-0015 clinical updates disclosed around the same time. The relatively contained moves in recent quarters may reflect the market's focus on clinical milestones rather than quarterly financial metrics for this pre-revenue company.

Part 2.2: Options Market Expected Move

The options market is pricing a 16.03% expected move for the upcoming earnings report, which is more than double the stock's average historical Day 0 move of 4.45% and significantly exceeds the average Day +1 move of 3.71%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting heightened uncertainty around ERAS-4001 data timing, cash burn trajectory, or potential pipeline updates. The wide divergence between the options-implied move and recent historical performance indicates either that the market is pricing in potential for a major catalyst beyond routine earnings, or that options premiums are elevated relative to likely outcomes.

Part 3: What Analysts Are Saying

Erasca currently holds a Strong Buy consensus among Wall Street analysts, with 8 Strong Buy ratings, 0 Moderate Buys, 3 Holds, 0 Moderate Sells, and 0 Strong Sells across 11 analysts covering the stock. This translates to an average recommendation of 4.45 on a 5-point scale, reflecting highly bullish sentiment. The mean price target stands at $23.70, implying 53% upside from the current price of $15.48.

The price target range spans from a low of $20.00 to a high of $33.00, indicating broad agreement on meaningful upside potential but divergent views on the ultimate magnitude. The $33 high target suggests some analysts see the potential for more than doubling from current levels if clinical execution delivers.

Sentiment has remained unchanged over the past month, with the analyst count and average recommendation holding steady at 4.45. This stability suggests the investment thesis remains intact despite the Q2 earnings miss, likely reflecting confidence in the ERAS-0015 clinical data and the company's strategic focus on high-value indications.

The consensus price target of $23.70 implies the Street believes Erasca's current valuation does not fully reflect the commercial potential of its RAS-targeting franchise, particularly if ERAS-0015 can advance successfully into registration-enabling trials and ERAS-4001 delivers differentiated Phase 1 data. However, with the stock trading well below the mean target, investors are pricing in significant execution risk around clinical development, regulatory pathways, and the competitive landscape in RAS-targeted therapies.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 40% Sell signal, a notable shift from 72% Sell one week ago and a dramatic reversal from 8% Buy one month ago. This recent weakening reflects deteriorating technical momentum despite the stock trading above most key moving averages.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, likely reflecting profit-taking or positioning ahead of earnings
• Medium-term (50% Sell): Matching sell signal in the intermediate timeframe suggests the weakness is not just a short-term fluctuation but part of a broader consolidation pattern
• Long-term (Hold): Neutral reading in the longer-term view indicates the underlying trend remains intact despite recent softness

Trend Characteristics: The signal is characterized as Weak and Weakening, suggesting the technical setup heading into earnings is fragile, with momentum indicators pointing to vulnerability rather than strength.

The stock is currently trading at $15.48, positioned above its 5-day ($14.74), 10-day ($14.68), 20-day ($14.56), 50-day ($14.98), and 200-day ($15.17) moving averages, but below its 100-day moving average ($16.58). This configuration shows the stock has maintained support above shorter-term averages but remains below the key 100-day level, which has acted as resistance.

The technical picture presents a mixed setup heading into earnings. While the stock holds above most moving averages—a typically constructive sign—the deteriorating Barchart Opinion signal and weakening momentum indicators suggest caution. The stock's position below the 100-day moving average at $16.58 represents a key resistance level that would need to be reclaimed for a more bullish technical outlook. The recent shift from an 8% Buy signal one month ago to a 40% Sell signal today indicates technical momentum has turned against the stock despite relatively stable price action, potentially reflecting distribution or waning buying interest. For a pre-revenue biotech, technical factors often take a back seat to clinical catalysts, but the current setup suggests the stock may be vulnerable to downside if earnings or pipeline updates disappoint, while a strong report with positive ERAS-4001 timing confirmation could provide the catalyst needed to break above the 100-day resistance and reverse the weakening trend.